MDxHealth (NASDAQ: MDXH) CCO reports multi-year share option grants
Rhea-AI Filing Summary
MDxHealth SA Chief Commercial Officer John Bellano filed an initial statement of beneficial ownership showing multiple share option awards over ordinary shares. The filing lists option grants from June 2019 through March 2025, with exercise prices ranging from 12.40 Euros to $1.47 per share and expirations between 2029-07-24 and 2035-04-11.
Several grants vest in three equal installments on each of the first three anniversaries of the grant date, while others vest upon the achievement of Company performance criteria evaluated by the Board of Directors at the end of specified performance periods. All positions are reported as held directly and relate to options, not current share trades.
Positive
- None.
Negative
- None.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
Bellano John
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
Holdings After Transaction:
Share Option — 555,200 shares (Direct)
Footnotes (12)
- F1. Represents options to purchase ordinary shares at a price per share of 12.40 Euros granted on June 17, 2019 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 24, 2019. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F2. Represents options to purchase ordinary shares at a price per share of 8.00 Euros granted on June 24, 2020 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 15, 2020. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F3. Represents options to purchase ordinary shares at a price per share of 8.00 Euros granted on June 24, 2020 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 15, 2020. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
- F4. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F5. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
- F6. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F7. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
- F8. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F9. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
- F10. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
- F11. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the performance periods.
- F12. Represents options to purchase ordinary shares at a price per share of $1.47 granted on March 26, 2025 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on April 11, 2025. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
Key Figures
Option grant 2019: 40,000 underlying shares
2020 option grants: 14,400 and 10,800 underlying shares
Large 2031 option tranches: 22,500 underlying shares (two grants)
+3 more
6 metrics
Option grant 2019
40,000 underlying shares
Share option expiring 2029-07-24 over ordinary shares
2020 option grants
14,400 and 10,800 underlying shares
Share options expiring 2030-07-15 over ordinary shares
Large 2031 option tranches
22,500 underlying shares (two grants)
Share options expiring 2031-07-03 over ordinary shares
2024 dollar-denominated options
100,000 and 65,000 underlying shares at $2.62
Options granted February 20, 2024, expiring 2034-06-22
2025 option grant
200,000 underlying shares at $1.47
Options granted March 26, 2025, expiring 2035-04-11
Euro-denominated 2022 grants
Exercise price 6.84 Euros
Options granted May 12, 2022, with time- and performance-based vesting
Key Terms
share option, ordinary shares, extraordinary general shareholders' meeting, vest in three equal installments, +1 more
5 terms
vest in three equal installments financial
"The options vest in three equal installments on each of the first three anniversaries"
performance criteria financial
"vested upon the achievement of certain Company performance criteria evaluated by the Board"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does MDXH’s Form 3 filing show about John Bellano’s holdings?
The Form 3 shows John Bellano holds several share options over MDxHealth ordinary shares, granted from 2019 to 2025. These options carry various exercise prices, expiration dates, and vesting schedules tied to time-based vesting and Company performance criteria.
How do John Bellano’s MDXH options typically vest?
Many of Bellano’s options vest in three equal installments on each of the first three anniversaries of the grant date. Other tranches vest upon achieving Company performance criteria that are evaluated by the Board of Directors at the end of defined performance periods.